SCHEMBL27137537

SCHEMBL27137537

O=S(=O)(Cl)c1cnn(-c2ccnc(C(F)(F)F)c2)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 1/20 0.40
▸ PTGS2 P35354 4/20 0.37
▸ SMARCA2 P51531 1/20 0.36
▸ SMARCA4 P51532 1/20 0.36
▸ CYP17A1 P05093 3/20 0.35
▸ LOXL2 Q9Y4K0 2/20 0.34
▸ RXRA P19793 2/20 0.34
▸ GRIN1 Q05586 2/20 0.34
▸ GRIN2B Q13224 2/20 0.34
▸ MALT1 Q9UDY8 2/20 0.33
▸ LOX P28300 1/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ KCNQ2 O43526 1/20 0.32
▸ PDE4B Q07343 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ ELANE P08246 1/20 0.31
▸ CHRM1 P11229 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27137469 0.75 RXRA (0.41) ARPTGS2SMARCA2SMARCA4CYP17A1
SCHEMBL27137532 0.74 RXRA (0.48) ARPTGS2SMARCA2SMARCA4LOXL2
SCHEMBL27137562 0.72 AR (0.41) ARPTGS2SMARCA2SMARCA4CYP17A1
SCHEMBL27137556 0.72 RXRA (0.42) ARPTGS2SMARCA2SMARCA4CYP17A1
SCHEMBL30015071 0.70 SMARCA2 (0.46) ARPTGS2SMARCA2SMARCA4LOXL2
SCHEMBL15454569 0.70 SMARCA2 (0.46) ARPTGS2SMARCA2SMARCA4LOXL2
SCHEMBL27137528 0.67 PKM (0.40) ARPTGS2LOXL2RXRAGRIN1
SCHEMBL27142132 0.67 PTGS2 (0.43) ARPTGS2LOXL2RXRAGRIN1
SCHEMBL15924205 0.64 RXRA (0.41) ARSMARCA2SMARCA4CYP17A1LOXL2
SCHEMBL15935175 0.64 RXRA (0.46) ARPTGS2SMARCA2SMARCA4CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577536-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY Hotspot Therapeutics, Inc. (US) 2025-07-02 — — EP disclosed
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 — — US disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 AR 3413/4885PTGS2 2618/4885SMARCA2 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback